Multiple Indications
LHRH receptors are over-expressed on the top ten solid tumor cancers by prevalence and various hematological malignancies, permitting AT-101 to target multiple cancer types, both at primary and metastatic stage.
Why Targeted Oncolytic for Cancer Treatment:
Oncolytic peptides have been studied as a treatment for cancer for more than 25 years. As anti-cancer agents, targeted oncolytic peptide conjugates offer the potential to provide unique advantages over current treatment approaches including the ability to target tumor cells with high specificity, low toxicity, and efficient tumor cell destruction.
Our Technology
The A28 Therapeutics Targeted Oncolytic Peptide (TOP™) Platform
A28’s targeted oncolytic peptide platform has been the subject of more than 70 pre-clinical studies and our lead compound has been clinically tested through a Phase 2a study, demonstrating an attractive safety profile and promising anti-tumor activity.
Watch the Video
How AT-101 Kills Cancer Cells
AT-101, A28 Therapeutics’ lead compound, is a conjugated targeted oncolytic peptide consisting of the cationic CLYP-71 oncolytic peptide conjugated to a ligand of the LHRH hormone. The LHRH receptor-targeting unit of AT-101 binds to cancer cells that overexpress LHRH receptors on their cell membranes, allowing the cell-killing oncolytic peptide unit to be attracted to the negatively charged cancer cell, resulting in targeted cancer cell death without harming healthy cells.
Watch the Video
AT-101: Pipeline in a Product
Multiple Combos
AT-101 synergizes with multiple types of cancer drugs, including Checkpoint and PARP inhibitors, as well as most types of chemotherapy.
Multiple Lines of Treatment
AT-101 has the potential to treat both advanced, metastatic cancers as second/third line therapy, as well earlier stage cancers, as first line therapy.
Our Company
With 70 years of combined experience in the life sciences, the A28 Therapeutics executive team is focused on developing innovative, safe and effective new treatments for cancer leveraging its novel targeted oncolytic peptide platform.
About UsPublications
April 8, 2026
November 6, 2024
October 6, 2024
Melittin and phospholipase A2: Promising anti-cancer candidates from bee venom
